GE Healthcare has been no stranger to dealmaking over the past year, and the company's CEO said it has no plans to let up.
Despite heavy competition, GE Healthcare will forge ahead with its ongoing acquisition spree, division chairman and CEO John Dineen has said. Execs are continuing their search for more information technology and life sciences diagnostic deals to help enhance the company's edge.
GE Healthcare is looking to cash in on the march toward hospital efficiency. It announced the acquisition of operating room management and analytics solutions provider CHCA Computer Systems today for an undisclosed amount. The deal is expected to close in the second quarter of 2014.
A GE Healthcare unit recalled hundreds of infant resuscitation devices in China after uncovering potential safety issues. The recall coincides with China's latest regulatory action, which calls for more stringent oversight of medical device makers.
GE Healthcare is going beyond just selling diagnostic imaging products in India to get involved, in part, in the distribution of care. The company will team up with a U.S. cancer healthcare operator to open cancer clinics that will rely on some of its key technology.
GE Healthcare has developed a discount molecular imaging system for cancer detection, intended for physicians practicing personalized medicine in emerging markets--especially India, where the devicemaker got help designing the system.
GE Healthcare completed its acquisition of three Thermo Fisher Scientific units. The $1.1 billion deal gives GE access to Thermo Fisher's profitable cell culture, gene modulation and magnetic bead businesses, helping the company expand its presence in protein analysis and medical diagnostics.
In 2013, a number of outside forces hammered the med tech industry. While things could have been better, most of the top 10 companies in the sector still enjoyed moderate year-over-year revenue gains.
The Wisconsin State Journal reported that the 630-employee medical device manufacturing plant in Madison, Wisconsin, run by GE Healthcare channels close to $342 million into the state's economy.
A U.K. diagnostics startup is off and running, backed by nearly $21.3 million in financing to support development of a PET imaging agent for recurrent prostate cancer licensed from GE Healthcare.